| Drug General Information |
| Drug ID |
D0U5UC
|
| Former ID |
DIB006339
|
| Drug Name |
KD025
|
| Indication |
Rheumatoid arthritis [ICD9: 710-719, 714; ICD10:M05-M06]
|
Phase 2 |
[1]
|
|---|
| Company |
Kadmon
|
| Structure |
|
Download
2D MOL
3D MOL
|
| Target and Pathway |
| Target(s) |
Rho associated protein kinase 2 |
Target Info |
Inhibitor |
[2]
|
|---|
|
KEGG Pathway
|
cGMP-PKG signaling pathway
|
|
cAMP signaling pathway
|
|
Chemokine signaling pathway
|
|
Sphingolipid signaling pathway
|
|
Vascular smooth muscle contraction
|
|
Wnt signaling pathway
|
|
Axon guidance
|
|
Focal adhesion
|
|
Platelet activation
|
|
Leukocyte transendothelial migration
|
|
Regulation of actin cytoskeleton
|
|
Oxytocin signaling pathway
|
|
Pathogenic Escherichia coli infection
|
|
Shigellosis
|
|
Salmonella infection
|
|
Pathways in cancer
|
|
Proteoglycans in cancer
|
|
PANTHER Pathway
|
Cytoskeletal regulation by Rho GTPase
|
|
Pathway Interaction Database
|
RhoA signaling pathway
|
|
Plasma membrane estrogen receptor signaling
|
|
Osteopontin-mediated events
|
|
PLK1 signaling events
|
|
PAR4-mediated thrombin signaling events
|
|
PAR1-mediated thrombin signaling events
|
|
Signaling events mediated by focal adhesion kinase
|
|
Reactome
|
EPHB-mediated forward signaling
|
|
EPHA-mediated growth cone collapse
|
|
G alpha (12/13) signalling events
|
|
Sema4D induced cell migration and growth-cone collapse
|
|
VEGFA-VEGFR2 Pathway
|
|
RHO GTPases Activate ROCKs
|
|
WikiPathways
|
G13 Signaling Pathway
|
|
Regulation of Actin Cytoskeleton
|
|
Focal Adhesion
|
|
JAK/STAT
|
|
Spinal Cord Injury
|
|
Pathogenic Escherichia coli infection
|
|
Leptin signaling pathway
|
|
Semaphorin interactions
|
|
Integrin-mediated Cell Adhesion
|
|
GPCR downstream signaling
|
|
MicroRNAs in cardiomyocyte hypertrophy
|
|
Androgen receptor signaling pathway
|
| References |
| REF 1 | ClinicalTrials.gov (NCT02317627) Study of of KD025 in Subjects With Psoriasis Vulgaris Who Failed First-Line Therapy. U.S. National Institutes of Health. |
|---|
| REF 2 | Selective oral ROCK2 inhibitor down-regulates IL-21 and IL-17 secretion in human T cells via STAT3-dependent mechanism. Proc Natl Acad Sci U S A. 2014 Nov 25;111(47):16814-9. |
|---|
